During her interview, Ms. Bresch argued that intermediaries like wholesalers, retailers and pharmacy benefit managers add to the final cost of EpiPens.
Dr. Miller responded to her comments in a later interview with CNBC, saying Express Scripts would love to see lower drug prices.
“If she wants to lower the price she can lower the price today,” said Dr. Miller. “We’d pass the savings that we take from the marketplace back to our plans.”
Within the past 18 months, Express Scripts’ copays for EpiPens have only increased from $73.03 to $73.50, according to Dr. Miller.
“Mylan has a monopoly and we’ve seen this time and time again. Because when companies have a monopoly for that temporary part of time, we actually can’t have the free market work,” said Dr. Miller. “We can’t pit competition against each other and drive down the price, and she’s capitalizing on it.”
More articles on supply chain:
Sen. Joe Manchin breaks silence on EpiPen controversy
5 latest FDA approvals
11 drugmakers with the highest profit margins
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
